Fintel reports that on July 7, 2025, Cantor Fitzgerald initiated coverage of Monopar Therapeutics (NasdaqCM:MNPR) with a ...

Wintermute gets Bitcoin (BTC) credit line from Cantor Fitzgerald. The credit line will enhance Wintermute’s capital-heavy OTC crypto trading operations. The deal signals a cautious return of ...

Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

Cantor Fitzgerald, a global financial services firm, announced on May 28, 2025, that it has entered into a definitive agreement to acquire UBS’s O’Connor alternatives investment platform.

In a report released today, Prakhar Agrawal from Cantor Fitzgerald reiterated a Buy rating on Oric Pharmaceuticals (ORIC – Research Report). The company’s shares opened today at $7.51.

The move will see O’Connor’s investment and support teams transferring to Cantor Fitzgerald’s Asset Management (CFAM) division upon closing. Moreover, the sale will also see O’Connor’s six investment ...

Cantor Fitzgerald also reaffirmed its Overweight rating, expressing confidence in ORIC’s management and the promising efficacy of ORIC-944. H.C. Wainwright raised its price target for ORIC ...

Cantor Fitzgerald Asset Management’s global investment platform consists of approximately $14.8 billion of assets under management across mutual funds, interval funds, exchange-traded funds ...